These outcomes suggest that NEO212 in combination with IR can better exploit the non-O6-methylguanine lesions created by NEO212 which lead to robust synergistic effects irrespective of the mechanism of resistance (i.e., either MGMT overexpression or MMR-deficiency). The gene discussed is MGMT; the disease is hyperinsulinemic hypoglycemia, familial, 4.